Excaliard Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Excaliard Pharmaceuticals, Inc.
Plus deals involving Takeda/Zedira/Dr. Falk, Lupin/Sunovion, Eucure/Syncromune, Hetero/Johnson & Johnson, Nitto Denko/Omega, Harbour BioMed/CSPC and Pregene/Bone Therapeutics.
Isis Pharmaceuticals founder, CEO and chairman Stanley Crooke knew it would take decades for antisense to prove itself. And while it's taken a few more years than expected for others to acknowledge the technology's potential, 2013 has been a good year for antisense in general and Isis in particular.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
- Antisense, Oligonucleotides
- Large Molecule
- Other Names / Subsidiaries
- Pfizer Inc.
- Excaliard Pharmaceuticals Inc.